Calcium Binding Protein 39 (CAB39) (Middle Region) Peptide
CAB39
适用: 人
宿主: 合成
BP, WB
-
- 抗原 See all CAB39 products
- CAB39 (Calcium Binding Protein 39 (CAB39))
- 蛋白结构域
- Middle Region
- 宿主
- 人
-
资源
- 合成
- 应用范围
- Blocking Peptide (BP), Western Blotting (WB)
- 产品特性
- This is a synthetic peptide designed for use in combination with anti-CAB39 antibody (Catalog #: ARP56877_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- 纯化方法
- Purified
-
-
- 应用备注
- Each Investigator should determine their own optimal working dilution for specific applications.
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 溶解方式
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- 浓度
- 1 mg/mL
- 缓冲液
- Final peptide concentration is 1 mg/mL in PBS.
- 注意事项
- Avoid repeated freeze-thaw cycles.
- 储存条件
- -20 °C
- 储存方法
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- 抗原
- CAB39 (Calcium Binding Protein 39 (CAB39))
- 别名
- CG4083 Peptide, Dmel\\CG4083 Peptide, Dmo25 Peptide, dMo25 Peptide, l(3)00274 Peptide, mo25 Peptide, fc06a03 Peptide, zgc:86716 Peptide, wu:fc06a03 Peptide, MGC78903 Peptide, CAB39 Peptide, MO25 Peptide, AA408805 Peptide, AA960512 Peptide, C78372 Peptide, MO25alpha Peptide, CG4083 gene product from transcript CG4083-RA Peptide, calcium binding protein 39 Peptide, calcium binding protein 39 L homeolog Peptide, Cab39 protein Peptide, Mo25 Peptide, cab39 Peptide, cab39.L Peptide, CAB39 Peptide, Bm1_33380 Peptide, Cab39 Peptide
- 背景
-
Together with the STE20-related adaptor-alpha (STRAD alpha) pseudo kinase, CAB39 forms a regulatory complex capable of stimulating the activity of STK11.
Alias Symbols: CGI-66, FLJ22682, MO25
Protein Interaction Partner: PRKAA1,STK11,STRADA,STRADB,BCKDK,CUL2,EBLN2,MOBKL3,RAD51,STK11,STRADA,TIMM13,VHL
Protein Size: 341 - 分子量
- 40 kDa
- 基因ID
- 51719
- NCBI登录号
- NM_016289, NP_057373
- UniProt
- Q9Y376
-
You are here:
